DOPPL – Disrupting healthcare with our high resolution, automated organoid factory

Exploiting the power of bioengineered technologies, DOPPL is the leading platform for high-throughput organoid culture and screenings for many tissue types and multiple phenotypic readouts. The DOPPL platform features a large cohort of organoid models and their associated data in a biobank, automated workflows for unlimited organoid expansion and use in large scale screens, and imaging capabilities. DOPPL engages in partnered projects for novel in vitro model generation and screening in drug development. Applications include patient-specific targeted therapy screening in cancer organoids, novel T-cell killing assay methodologies for immuno-oncology studies, toxicity assessment and transport studies on gastrointestinal organoids, and on organoid-based blood-brain barrier model.